Get the Stockscreener App
3.08
0.65%
-0.02
After Hours:
3.16
0.08
+2.60%
Aquestive Therapeutics Inc stock is traded at $3.08, with a volume of 1.05M.
It is down -0.65% in the last 24 hours and down -12.50% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
See More
Previous Close:
$3.10
Open:
$3.15
24h Volume:
1.05M
Relative Volume:
0.68
Market Cap:
$280.83M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-8.4592
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-1.60%
1M Performance:
-12.50%
6M Performance:
-18.95%
1Y Performance:
+29.41%
1-Day Range:
$3.02
$3.17
1-Week Range:
$2.96
$3.19
52-Week Range:
$2.24
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.08 | 280.83M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
172.71 | 77.92B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.70 | 43.43B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.27B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.84 | 20.21B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.52B | 2.24B | 385.90M | 440.10M | 3.73 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Piper starts Aquestive at overweight, cites allergy reaction treatment - MSN
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - MSN
Institutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Cantor Fitzgerald Weighs in on AQST FY2025 Earnings - MarketBeat
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Anaphylaxis Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics - Barchart
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trendsTechnavio - The Malaysian Reserve
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress - TipRanks
Aquestive Therapeutics Provides Business Update - citybiz
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives - The Manila Times
Aquestive Therapeutics Targets 2026 Launch for Anaphylm as FDA Approves Pediatric Seizure Drug - StockTitan
Aquestive Therapeutics: Five Foci For 2025 (NASDAQ:AQST) - Seeking Alpha
Geode Capital Management LLC Has $8.31 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Barclays PLC Buys 73,542 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What Analysts Were Expecting After Aquestive Therapeutics Inc (NASDAQ: AQST) rose 4.21% - Stocks Register
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp - Defense World
State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Stifel Financial Corp Sells 301,538 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Aquestive shares reiterated at Buy by analyst as FDA grants ODE to Libervant - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Set Expectations for AQST FY2024 Earnings - Defense World
Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment - Yahoo Finance
Aquestive Therapeutics Receives U.S. FDA Orphan Drug - GlobeNewswire
Cantor Fitzgerald Forecasts AQST FY2024 Earnings - MarketBeat
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25% - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets - Defense World
Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Charles Schwab Investment Management Inc. Purchases 9,268 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics' SWOT analysis: stock poised for growth with innovative epinephrine delivery - Investing.com Australia
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Yahoo Finance UK
Aquestive Therapeutics (NASDAQ:AQST) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Aquestive Therapeutics stock initiated at Overweight by Fitzgerald, eyes strong 2025 catalysts - Investing.com UK
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year - Yahoo Finance
Aquestive Therapeutics (NASDAQ:AQST) shareholders have earned a 88% return over the last year - Simply Wall St
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth - Investing.com Nigeria
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):